Article Data

  • Views 241
  • Dowloads 120

Original Research

Open Access

Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors

  • İ. Alanbay1,*,
  • E. Aktürk1
  • H. Coksuer1
  • C.M. Ercan1
  • E. Karaşahin1
  • M. Dede1
  • M.C. Yenen1
  • H. Ozan2
  • S. Dilek3

1Obstetrics and Gynecology Department, Gulhane Military Medical Faculty, Ankara, Turkey

2Obstetrics and Gynecology Department, Uludag University Medical Faculty, Bursa, Turkey

3Obstetrics and Gynecology Department, Mersin University Medical Faculty, Mersin, Turkey

DOI: 10.12892/ejgo20120125 Vol.33,Issue 1,January 2012 pp.25-30

Published: 10 January 2012

*Corresponding Author(s): İ. Alanbay E-mail:


Objective: The aim of this study was to assess tumor markers and clinicopathological findings of patients with serous and mucinous borderline ovarian tumor (BOT) features. Methods: The study consisted of 50 patients that were diagnosed with and treated for BOT between 2005- 2010 in three centers. CA125, CA19-9, and CA125+CA19-9 levels and clinicopathological features were compared in serous and mucinous histotypes. In serous and mucinous BOTs, correlations between tumor markers and demographics such as age, menopausal status, parity, clinical findings (stage, relapse, adjuvant chemotherapy, cytology, lymph node involvement and tumoral morphology (cystic-solid content, papilla, septation) were evaluated. Results: There were no significant differences between serous and mucinous tumors in the clinicopathological features such as stage, tumor markers, age, menopausal status, or cytology. In serous BOTs we found a significant relation between elevated CA 125+ CA 19-9, CA 19-9 and recurrence (p < 0.05). Also there was a significant relation between elevated CA 125+ CA 19-9, CA 19-9 and cytology positivity (p < 0.05). We found a significant relation in serous BOTs between elevated CA125+CA19-9, adjuvant chemotherapy and lymph node metastases (p < 0.05). Also In mucinous BOTs with papilla formation we found a significant relation between elevated CA125 and CA 125+ CA19-9 (p < 0.05). There was significant relation between cytology positivity and elevated CA 19-9 in mucinous BOTs (p < 0.05). Conclusion: Serum tumor markers of serous and mucinous BOTs were different in relation to their clinicopathological features. This may reflect differences of serous and mucinous BOTs.


Borderline ovarian tumor; Serous; Mucinous borderline ovarian tumor; Tumor markers

Cite and Share

İ. Alanbay,E. Aktürk,H. Coksuer,C.M. Ercan,E. Karaşahin,M. Dede,M.C. Yenen,H. Ozan,S. Dilek. Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors. European Journal of Gynaecological Oncology. 2012. 33(1);25-30.


[1] Taylor H.C.: “Malignant and semimalignant tumors of the ovary”. Surg. Gynecol. Obstet., 1929, 48, 204.

[2] International Federation of Gynecology and Obstetrics Classification and staging of malignant tumors in the female pelvis.Acta Obstet. Gynecol. Scand., 1971, 50, 1.

[3] Tinelli R., Tinelli A., Tinelli F.G., Cicinelli E., Malvasi A.: “Conservative surgery for borderline ovarian tumors: a review”. Gynecol. Oncol., 2006, 100, 185.

[4] Cadron I., Leunen K., Van Gorp T., Amant F., Neven P., Vergote I.: “Management of borderline ovarian neoplasms”. J. Clin. Oncol., 2007, 25, 2928.

[5] Tinelli R., Malzoni M, Cosentino F., Perone C., Tinelli A., Malvasi A. et al.: “Feasibility, safety, and efficacy of conservative laparoscopic treatment of borderline ovarian tumors”. Fertil. Steril., 2009, 92, 736.

[6] Benito V., Lubrano A., Arencibia O., Medina N., Alvarez Eva E., Andujar M. et al.: “Serous and mucinous borderline ovarian tumors: are there real differences between these two entities”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2010, 153, 188.

[7] Tamakoshi K., Kikkawa F., Shibata K., Tomoda K., Obata N.H., Wakahara F. et al.: “Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor”. Gynecol. Oncol., 1996, 62, 67.

[8] Gotlieb W.H., Soriano D., Achiron R., Zalel Y., Davidson B., Kopolovic J. et al.: “CA125 measurement and ultrasonography inborderline tumors of the ovary”. Am. J. Obstet. Gynecol., 2000, 183, 541.

[9] Engelen M., Bruijn H., Hollema H., Ten Hoor K., Willemse P., Aalders J. et al.: “Serum Ca 125, Carcinoembryogenic antigen and Ca 19. 9 as tumor markers in borderline ovarian tumors”. Gynecol. Oncol., 2000, 78, 16.

[10] Ayhan A., Guven S., Guven E.S., Kucukali T.: “Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?”. Acta Obstet. Gynecol. Scand., 2007, 86, 484.

[11] Kolwijck E., Chris M.G.T., Bulten J., Leon F.A.G. Massuger: “Preoperative CA-125 levels in 123 patients with borderline ovarian tumors a retrospective analysis and review of the literature”. Int. J. Gynecol. Cancer, 2009, 19, 1335.

[12] Shih K.K., Zhou Q., Huh J, Morgan J.C., Iasonos A., Aghajanian C. et al.: “Risk factors for recurrence of ovarian borderline tumors”. Gynecol. Oncol., 2011, 120, 480.

[13] Poncelet C., Fauvet R., Yazbeck C., Coutant C., Darai E.: “Impact of serum tumor marker determination on the managementof women with borderline ovarian tumors: Multivariate analysis of a French multicentre study”. EJSO, 2010, 36, 1066.

[14] FIGO Committee on Gynecologic Oncology: “Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia”. Int. J. Gynecol. Obstet., 2009, 105, 3.

[15] Acs G.: “Serous and mucinous borderline (low malignant potential) tumors of the ovary”. Am. J. Clin. Pathol., 2005, 123, S13.

[16] Ren J., Peng Z., Yang K.: “A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors”. Gynecol. Oncol., 2008, 110, 162.

[17] Kikkawa F., Nawa A., Kajiyama H., Shibata K., Ino K., Nomur S.: “Clinical characteristics and prognosis of mucinous tumors of the ovary”. Gynecol. Oncol., 2006, 103, 171.

[18] Wu T.I., Lee C.L., Wu M.Y., Hsueh S., Huang K.G., Yeh C.J. et al.: “Prognostic factors predicting recurrence in borderline ovarian tumors”. Gynecol. Oncol., 2009, 114, 237.

[19] Lenhard M.S., Nehring S., Nage D., Mayr D., Kirschenhofer A., Hertlein L. et al.: “Predictive value of CA 125 a nd CA 72-4 in ovarian borderline tumors”. Clin. Chem. Lab. Med., 2009, 47, 537.

[20] Rice L.W., Lage J.M., Berkowitz R.S., Goodman A., Muto M.G., Knapp R.C. et al.: “Preoperative serum CA-125 levels in border-line tumors of the ovary”. Gynecol. Oncol., 1992, 46, 226.

[21] Cadron I., Amant F., Van Gorp T., Neven P., Leunen K., Vergote I.: “The management of borderline tumours of the ovary”. Curr. Opin. Oncol., 2006, 18, 488.

[22] Fadare O.: “Recent developments on the significance and pathogenesis of lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors)”. Int. J. Gynecol. Cancer, 2009, 19, 103.

[23] Exacoustos C., Romanini M.E., Rinaldo D., Amoroso C., Szabolcs B., Zupi E., Arduni D.: “Preoperative sonographic features of bor-derline ovarian tumors”. Ultrasound Obstet. Gynecol., 2005, 25, 50.

[24] Pascual M.A., Tresserra F., Grases P.J., Labastida R., Dexeus S.:“Borderline cystic tumors of the ovary: gray-scale and color Doppler sonographic findings”. J. Clin. Ultrasound, 2002, 30, 76.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time